New combo therapy aims to control advanced breast cancer
NCT ID NCT04288089
First seen Mar 04, 2026 · Last updated May 01, 2026 · Updated 10 times
Summary
This early-phase study tests a new drug (H3B-6545) combined with palbociclib in women with advanced or metastatic ER+ HER2- breast cancer. The main goal is to find the safest dose and understand side effects. About 31 women who have already received prior treatment will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169, United States
-
Florida Cancer Specialists South - SCRI - PPDS
Sarasota, Florida, 34232, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Royal Marsden NHS Foundation Trust
London, United Kingdom
-
Royal Marsden NHS Foundation Trust
Sutton, United Kingdom
-
Saint Luke's Cancer Institute
Kansas City, Missouri, 64111, United States
-
Sarah Cannon Research Institute UK - SCRI
London, United Kingdom
-
Tennessee Oncology, PLLC - SCRI - PPDS
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.